Literature DB >> 29323913

Nanoparticles with CD44 Targeting and ROS Triggering Properties as Effective in Vivo Antigen Delivery System.

Xiaoyu Liang1, Xuanling Li1, Jianwei Duan1, Youlu Chen1, Xiaoli Wang1, Liyun Pang1, Deling Kong1,2, Bing Song3, Chen Li1, Jing Yang1.   

Abstract

Currently, development of subunit vaccine based on recombinant antigens or peptides has gradually become an important alternative option for traditional vaccine. However, induction of potent immune response with desired efficacy remains a major challenge. The nanoparticle-based antigen delivery system has been considered a potential carrier system to improve the efficacy of subunit vaccine. In the present study, we have designed an immune-stimulatory delivery system by conjugating three-armed PLGA to PEG via the peroxalate ester bond which is sensitive to hydrogen peroxide (H2O2), a major reactive oxygen species (ROS). Hyaluronic acid (HA), a ligand for CD44 receptors was also modified onto the outer shell of the 3s-PLGA-PEG nanoparticles to promote immune cell uptake. For in vitro and in vivo immune response assessment, a model antigen ovalbumin (OVA) was enclosed within the core of the 3s-PLGA-PEG nanoparticles to form 3s-PLGA-PO-PEG/HA nanoparticles (PHO NPs). Our results showed that the PHO NPs enhanced dendritic cell maturation, antigen uptake, and antigen presentation in vitro, likely due to enhanced lysosomal escape. In vivo experiments further revealed that the PHO nanovaccine robustly promoted OVA-specific antibody production and T cell response accompanied by modest stimulation of memory T cells. In summary, the ROS-responsive PHO NPs with modified HA may be an effective vehicle antigen delivery system to promote antigen-induced immune response.

Entities:  

Keywords:  ROS triggered; hyaluronic acid modified; immune response; nanoparticles

Mesh:

Substances:

Year:  2018        PMID: 29323913     DOI: 10.1021/acs.molpharmaceut.7b00890

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  6 in total

Review 1.  Innovations in lymph node targeting nanocarriers.

Authors:  Jihoon Kim; Paul A Archer; Susan N Thomas
Journal:  Semin Immunol       Date:  2021-11-24       Impact factor: 11.130

2.  Selective Anticancer Therapy Based on a HA-CD44 Interaction Inhibitor Loaded on Polymeric Nanoparticles.

Authors:  José M Espejo-Román; Belén Rubio-Ruiz; Victoria Cano-Cortés; Olga Cruz-López; Saúl Gonzalez-Resines; Carmen Domene; Ana Conejo-García; Rosario M Sánchez-Martín
Journal:  Pharmaceutics       Date:  2022-04-04       Impact factor: 6.525

3.  Mannose-Modified Multi-Walled Carbon Nanotubes as a Delivery Nanovector Optimizing the Antigen Presentation of Dendritic Cells.

Authors:  Zhipeng Dong; Qiyan Wang; Ming Huo; Nanxia Zhang; Bingxia Li; Hongmei Li; Yisong Xu; Meng Chen; Hao Hong; Yue Wang
Journal:  ChemistryOpen       Date:  2019-07-12       Impact factor: 2.911

4.  Anti-Dengue ED3 Long-Term Immune Response With T-Cell Memory Generated Using Solubility Controlling Peptide Tags.

Authors:  Mohammad M Islam; Shiho Miura; Mohammad N Hasan; Nafsoon Rahman; Yutaka Kuroda
Journal:  Front Immunol       Date:  2020-03-17       Impact factor: 7.561

5.  Hybrid Nanoparticles Modified by Hyaluronic Acid Loading an HSP90 Inhibitor as a Novel Delivery System for Subcutaneous and Orthotopic Colon Cancer Therapy.

Authors:  Chenwei Pan; Tiaotiao Zhang; Shaoxun Li; Zhihua Xu; Binhui Pan; Sheng Xu; Shuanghong Jin; Guangrong Lu; Shouxing Yang; Zhanxiong Xue; Ping Chen; Xian Shen; Fangyan Wang; Changlong Xu
Journal:  Int J Nanomedicine       Date:  2021-03-02

Review 6.  Tumor-Microenvironment-Responsive Nanomedicine for Enhanced Cancer Immunotherapy.

Authors:  Shaojun Peng; Fengfeng Xiao; Meiwan Chen; Huile Gao
Journal:  Adv Sci (Weinh)       Date:  2021-11-19       Impact factor: 16.806

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.